ARN 077

• Description:

  ARN 077 is a potent and selective N-acylethanolamine acid amidase (NAAA) inhibitor with an IC50 of 7 nM for human NAAA[1]. ARN 077 significantly increases palmitoyl ethanolamine (PEA) levels within the CNS and has broad antinociceptive activity in mice and rats[2].

• Product Name Alternative:

  URB913

• UNSPSC:

  12352005

• Target:

  Ceramidase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ARN_077.html

• Purity:

  98.83

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C(OCCCCCC1=CC=CC=C1)N[C@@H]2[C@H](C)OC2=O

• Molecular Formula:

  C16H21NO4

• Molecular Weight:

  291.34

• References & Citations:

  [1]Sasso O, et al. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain. 2013 Mar;154 (3) :350-60.|[2]Davis MP, et al. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin Investig Drugs. 2014 Aug;23 (8) :1123-40.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1373625-34-3